Premium
A Real‐World Evaluation of Oral Vancomycin for Severe Clostridium difficile Infection: Implications for Antibiotic Stewardship Programs
Author(s) -
Le Frank,
Arora Vaneet,
Shah Dhara N.,
Salazar Miguel,
Palmer Hannah R.,
Garey Kevin W.
Publication year - 2012
Publication title -
pharmacotherapy: the journal of human pharmacology and drug therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.227
H-Index - 109
eISSN - 1875-9114
pISSN - 0277-0008
DOI - 10.1002/phar.1002
Subject(s) - medicine , clostridium difficile , vancomycin , metronidazole , antibiotics , antimicrobial stewardship , intensive care medicine , retrospective cohort study , disease , prospective cohort study , cohort study , antibiotic resistance , genetics , bacteria , microbiology and biotechnology , biology , staphylococcus aureus
Study Objective To assess antibiotic treatment patterns and clinical outcomes of patients with Clostridium difficile infection ( CDI ) based on underlying severity of CDI disease. Design Retrospective analysis of data from a prospective cohort study. Setting Large tertiary care university hospital. Patients One hundred forty‐four patients (mean ± SD age 63 ± 17 yrs) with CDI who received metronidazole (intravenous or oral) or oral vancomycin as their initial therapy option between 2006 and 2008. Measurements and Main Results Patients were stratified by severity of illness and treatment, and outcomes assessed were clinical response, relapse of disease, all‐cause inpatient mortality, and length of hospital stay. Mild‐moderate CDI disease was present in 85 patients (59%) and severe disease in 59 patients (41%). Overall, oral vancomycin was given to 16 patients (11%); use of this drug did not differ according to severity of infection. Among patients with severe disease, clinical success occurred in 32 (63%) of 51 patients given metronidazole and in all 8 patients (100%) given vancomycin (p=0.04). Inpatient mortality and hospital length of stay were lower in patients with severe CDI who were given oral vancomycin, although these results were not statistically significant. Conclusion Oral vancomycin was not commonly used for severe CDI . An improved clinical response rate was observed in patients with severe CDI given oral vancomycin; this outcome supported results from clinical trials. Antibiotic stewardship teams could play a major role in providing guidance on CDI treatment based on severity.